Vir director receives stock and option awards
Vir Biotechnology director Norbert W. Bischofberger reported equity awards rather than open-market trades.
Rhea-AI Filing Summary
Vir Biotechnology director Norbert W. Bischofberger reported equity awards rather than open-market trades. He received 8,000 shares in the form of restricted stock units granted under Vir Biotechnology’s Equity Incentive Plan, which will vest in full on May 27, 2027. He was also granted a stock option covering 16,000 shares of common stock at an exercise price of $9.10 per share, vesting on the same date and expiring on May 26, 2036. After these grants, he holds 21,333 shares of common stock directly and 10,667 shares indirectly through Nextquest, LLC, where he is a managing member.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 24,000 shares
Grant/Award
3 txns
Insider
BISCHOFBERGER NORBERT W
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 16,000 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 8,000 | $0.00 | $0.00 |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 16,000 contracts (Direct);
Common Stock — 21,333 shares (Direct);
Common Stock — 10,667 shares (Indirect, See footnote)
Footnotes (4)
- F1. Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.
- F2. The RSUs will vest in full on May 27, 2027.
- F3. The shares are held in the name of Nextquest, LLC, of which the Reporting Person is a managing member.
- F4. The shares subject to the stock option will vest and become exercisable in full on May 27, 2027.
Key Figures
RSU grant: 8,000 shares
Stock option grant: 16,000 shares
Option exercise price: $9.10 per share
+5 more
8 metrics
RSU grant
8,000 shares
Restricted stock units granted on May 27, 2026
Stock option grant
16,000 shares
Option on common stock granted on May 27, 2026
Option exercise price
$9.10 per share
Conversion or exercise price for 16,000-share option
RSU vesting date
May 27, 2027
RSUs vest in full on this date
Option vesting date
May 27, 2027
Stock option becomes fully exercisable on this date
Option expiration date
May 26, 2036
Final expiration date of the stock option
Direct holdings after grant
21,333 shares
Common stock directly owned following reported transactions
Indirect holdings
10,667 shares
Common stock held indirectly through Nextquest, LLC
Key Terms
restricted stock units (RSUs), Equity Incentive Plan, Stock Option (Right to Buy), exercise price, +1 more
5 terms
restricted stock units (RSUs) financial
"Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan."
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
Equity Incentive Plan financial
"Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan."
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) reported as a derivative security."
exercise price financial
"The stock option has a conversion or exercise price of 9.1000."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest and become exercisable financial
"The shares subject to the stock option will vest and become exercisable in full on May 27, 2027."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Vir Biotechnology (VIR) director Norbert Bischofberger report in this Form 4?
He reported compensation-related equity awards, not market trades. The filing shows grants of restricted stock units and a stock option, increasing his direct and indirect holdings in Vir Biotechnology common stock without any reported open-market buying or selling.
What stock option did Norbert Bischofberger receive from Vir Biotechnology (VIR)?
He received a stock option for 16,000 shares of common stock. The option has an exercise price of $9.10 per share, will vest and become exercisable in full on May 27, 2027, and is scheduled to expire on May 26, 2036.
Are Norbert Bischofberger’s Vir Biotechnology (VIR) transactions open-market buys or sells?
No, the reported transactions are equity grants, not open-market trades. The Form 4 characterizes them as awards of restricted stock units and a stock option, both coded as acquisition transactions, with no reported purchases or sales in the open market.
When will Norbert Bischofberger’s Vir Biotechnology (VIR) RSUs and options vest?
Both the RSUs and the stock option are scheduled to vest on May 27, 2027. On that date, the 8,000 RSUs are expected to vest in full, and the 16,000-share stock option is expected to become fully exercisable, according to the Form 4 footnotes.
AI-generated analysis. How Rhea-AI works. Not financial advice.
